Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers

Next Previous
Trial Profile

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; E 602 (Primary)
  • Indications Advanced breast cancer; Colon cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms GLIMMER-01
  • Sponsors Palleon Pharmaceuticals

Most Recent Events

  • 27 Mar 2025 Status changed from active, no longer recruiting to completed.
  • 08 Nov 2024 According to a Palleon Pharmaceuticals media release, company to present result from this trial in both rapid oral and poster presentations on Saturday, November 9 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, Texas.
  • 08 Nov 2024 Results presented in the Palleon Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top